Rating Change
Chardan Capital reiterated its Buy rating on Adagene Inc. (NASDAQ:ADAG) on October 28, 2026.
Chardan Capital reiterated its Buy rating on Adagene Inc. (NASDAQ:ADAG) on October 28, 2026.

At publication ·
Adagene Inc. (NASDAQ:ADAG) · reiterate
At a glance
Chardan Capital reiterated its Buy rating on Adagene Inc. (NASDAQ:ADAG) on October 28, 2026.
Adagene Inc. operates in the Healthcare sector. The stock currently trades at $2.67 with a market capitalization of $111.6M. The stock has gained 44.1% over the past 52 weeks.
Analyst coverage from Chardan Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Adagene Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 28, 2026 | Chardan Capital | Buy | N/A |
| Oct 19, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 14, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 10, 2026 | Chardan Capital | Buy | N/A |
| Apr 06, 2026 | Guggenheim | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ADAG Stock Page
A rating of Buy from Chardan Capital reflects the analyst's outlook on Adagene Inc. (NASDAQ:ADAG). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ADAG forecast page.
Current market data
NASDAQ · ADAG
$2.41
Up: +$0.06 · +2.55%
Live quote updated
Keep reading